Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss

Caribou Biosciences Inc (NASDAQ:CRBU) Reports Q2 2025 Earnings: Mixed Results and Market Reaction

Caribou Biosciences Inc (NASDAQ:CRBU) released its second-quarter 2025 financial results, posting revenue of $2.67 million, which exceeded analyst estimates of $2.51 million. However, the company reported a net loss per share of $0.58, missing the consensus EPS estimate of -$0.40. The market reaction has been muted, with shares dipping slightly in after-hours trading, reflecting investor caution amid mixed financial performance.

Key Financial Takeaways

• Revenue: $2.67M (vs. $2.51M estimate) – beat by ~6.4%.
• EPS: -$0.58 (vs. -$0.40 estimate) – miss by ~45%.
• Cash Position: $183.9M in cash and equivalents, expected to fund operations into H2 2027.
• R&D Expenses: Declined to $27.7M from $35.5M YoY due to pipeline prioritization and cost reductions.
• Non-GAAP Net Loss: $32.8M (excluding $21.3M in non-cash impairment charges).

The revenue beat suggests continued traction in licensing and collaborations, but the wider-than-expected loss reflects ongoing investment in clinical programs. The company’s cash runway extension into late 2027 provides stability, though investors appear focused on execution risks in upcoming clinical data readouts.

Clinical Progress and Upcoming Milestones

Caribou remains on track to report key clinical updates in the second half of 2025:

• CB-010 (ANTLER Phase 1 for large B-cell lymphoma): Data from a 20-patient confirmatory cohort expected, with potential pivotal trial discussions with the FDA.
• CB-011 (CaMMouflage Phase 1 for multiple myeloma): Dose escalation data anticipated, including safety and efficacy for at least 25 patients.

CEO Rachel Haurwitz emphasized the potential of Caribou’s allogeneic CAR-T therapies, but the market’s subdued reaction suggests investors are awaiting more concrete clinical validation.

Market Reaction and Forward Estimates

Despite the revenue beat, the EPS miss and lack of upward revisions in forward guidance appear to be weighing on sentiment. Analysts currently project:

• Q3 2025 Revenue Estimate: $2.59M
• Full-Year 2025 Revenue Estimate: $10.95M
• Q3 2025 EPS Estimate: -$0.38

The absence of a strong post-earnings rally indicates that investors are looking for clearer signs of commercial viability or accelerated clinical progress.

Conclusion

Caribou Biosciences continues to advance its CRISPR-based cell therapies, but the financials reflect the high costs of clinical development. The company’s ability to deliver robust data in H2 2025 will be critical in determining whether it can regain momentum.

For more detailed earnings estimates and historical performance, view the full Caribou Biosciences earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.